Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | AAK1 | Q2M2I8 | 9/20 | 0.47 |
| ▸ | TERT | O14746 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13815099 | 0.96 | AAK1 (0.48) | SUV39H2LTA4HAAK1TERTMEN1 | |
| Delparantag SCHEMBL10262676 | 0.91 | ERAP2 (0.47) | SUV39H2LTA4HAAK1TERTMMP2 | |
| Delparantag SCHEMBL19445838 | 0.91 | ERAP2 (0.47) | SUV39H2LTA4HAAK1TERTMMP2 | |
| Delparantag SCHEMBL31024631 | 0.91 | ERAP2 (0.47) | SUV39H2LTA4HAAK1TERTMMP2 | |
| Delparantag SCHEMBL10267622 | 0.91 | ERAP2 (0.47) | SUV39H2LTA4HAAK1TERTMMP2 | |
| Delparantag SCHEMBL10260914 | 0.91 | ERAP2 (0.47) | SUV39H2LTA4HAAK1TERTMMP2 | |
| SCHEMBL15138936 | 0.91 | ERAP2 (0.47) | SUV39H2LTA4HAAK1TERTMMP2 | |
| SCHEMBL21372057 | 0.91 | SUV39H2 (0.45) | SUV39H2LTA4HAAK1TERTMEN1 | |
| SCHEMBL21865048 | 0.91 | SUV39H2 (0.45) | SUV39H2LTA4HAAK1TERTMEN1 | |
| Delparantag SCHEMBL19445836 | 0.91 | ERAP2 (0.47) | SUV39H2LTA4HAAK1TERTMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051762-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | POLYMEDIX, INC. | 2014-02-20 | — | — | US | disclosed |
| US-7553876-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2009-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051762-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | VEGFA, VHL, PGF | SUV39H2 563/4885LTA4H 3701/4885AAK1 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.